Is Cardinal Health (CAH) Stock Too Rich After Raised Guidance?

Cardinal Health has surged over recent years, and fresh earnings strength keeps pushing the story forward, so the live question for investors is whether that share price now lines up with what the business is actually earning.

• Over the past 5 years the stock has delivered a very large gain of about 7x, which puts a lot of weight on whether current earnings can support a valuation at this level.
• Recent profit performance and higher earnings expectations point to stronger income generation, which can reshape how much investors are willing to pay for each dollar of Cardinal Health's earnings.
• The analysts covering Cardinal Health have run their own numbers. See what analysts think Cardinal Health's shares could be worth.

The issue now is whether Cardinal Health's current share price is justified by its earnings when set against the Fair Ratio benchmark.

If you want to stress test this same Fair Ratio earnings lens beyond Cardinal Health, line it up against a wider field of 42 high quality undervalued stocks.

Does Cardinal Health Look Pricey on Earnings?

The P/E lens fits Cardinal Health because recent results and guidance put earnings front and center for how the stock is being judged. Cardinal Health trades on a P/E of about 36.2x, which is higher than the Healthcare sector average of roughly 24.9x and above the peer group near 26.5x. That is a meaningful premium for each dollar of profit.

The Fair Ratio, which reflects what investors might typically pay for Cardinal Health after factoring in its business mix, risk profile and analyst expectations, sits below the current multiple, so the shares screen as overvalued on this framework. Because the latest earnings beat and raised EPS guidance have already pushed the valuation well above these anchors, you need to decide whether that strength justifies paying up for the stock at this P/E level. Explore the numbers behind Cardinal Health's P/E valuation.

The Cardinal Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Cardinal Health pick up where the P/E puzzle leaves off and explain which assumptions about growth, profitability and future earnings would need to hold for the stock to be worth meaningfully more or less than today’s price on the Community page. Each narrative links its number to a clear view of how Cardinal Health's growth, margins and risk profile might evolve, giving you something concrete to revisit as fresh information arrives.

One of the top community narratives on Cardinal Health: roughly fairly valued

"The main requirement is continued execution in scaling specialty, Biopharma Solutions, and at Home chronic care, while keeping quality controls…"

Discover why this Narrative puts Cardinal Health at roughly fairly valued.

An open question for Cardinal Health that only the next few years can answer

Price and current earnings tell only part of the Cardinal Health story, because analysts have mapped out where they think this business could be several years from now. Explore where analysts expect Cardinal Health to be in a few years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com